Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03060980
Other study ID # ITCA 650-CLP-203
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date March 3, 2017
Est. completion date January 26, 2018

Study information

Verified date March 2019
Source Intarcia Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 3b, open-label, randomized, multicenter, efficacy, safety, and tolerability study of ITCA 650 compared to Empagliflozin and to Glimepiride, as add-on therapy to Metformin in patients with Type 2 diabetes.


Recruitment information / eligibility

Status Terminated
Enrollment 245
Est. completion date January 26, 2018
Est. primary completion date January 26, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Diagnosis of T2D 3 months prior to the Screening Visit.

- Body mass index (BMI) between =25 to =45 kg/m2 at the Screening Visit.

- Glycosylated hemoglobin A1c (HbA1c) =7.5 and =10.5%. 5. 6. On a stable (3 months prior to the Screening Visit) treatment regimen of metformin monotherapy of =1500 mg/day).

Exclusion Criteria:

- History of type 1 diabetes.

- Prior participation in a clinical study involving ITCA 650.

- Treatment with any GLP-1 receptor agonist (eg, liraglutide, exenatide) within 6 months prior to Screening.

- History or evidence, within the last 6 months prior to the Screening Visit, of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke.

- History or evidence of acute or chronic pancreatitis.

- History of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2.

- Treatment of medications that affect GI motility.

- History of hypersensitivity to exenatide, empagliflozin, or glimepiride or to one of its excipients.

- Women that are pregnant, lactating, or planning to become pregnant.

- Chronic (>10 consecutive days) treatment with systemic corticosteroids within 8 weeks prior to screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ITCA 650 20/60 mcg/day
ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
Empagliflozin (oral)
10 mg/day and 25 mg/day
Glimepiride (oral)
1-6 mg/day

Locations

Country Name City State
Canada Milestone Research London Ontario
Canada Bailey Clinic Red Deer Alberta
Canada Bluewater Clinical Research Group Sarnia Ontario
Canada Dr. Anil K. Gupta Medicine Professional Corporation Toronto Ontario
Canada CookMed Research Victoria British Columbia
United States Radiant Research Akron Ohio
United States Albany Medical College Albany New York
United States Anaheim Clinical Trials Anaheim California
United States Community Hospital of Anderson and Madison County, Inc. Anderson Indiana
United States Atlanta Center for Medical Research Atlanta Georgia
United States Primary Care Research Group Atlanta Georgia
United States Maine Research Associates Auburn Maine
United States Heartland Research Associates, LLC Augusta Kansas
United States Denver VA Medical Center Aurora Colorado
United States DCT-AACT, LLC dba Discovery Clinical Trials Austin Texas
United States Pennington Biomedical Research Center Baton Rouge Louisiana
United States Ehrhardt Clinical Research, LLC Belton Missouri
United States Joslin Diabetes Center Boston Massachusetts
United States Mercury Street Medical Group Butte Montana
United States Radiant Research Carlsbad California
United States Radiant Research Centennial Colorado
United States American Health Research Charlotte North Carolina
United States Michigan Avenue Internists Chicago Illinois
United States Sentral Clinical Research Services, LLC Cincinnati Ohio
United States Ericksen Research and Development, LLC Clinton Utah
United States Colorado Springs Health Partners - East Colorado Springs Colorado
United States Aventiv Research Columbus Ohio
United States Canyon Medical Center, LLC Columbus Ohio
United States Nature Coast Clinical Reseaerch - Crystal River Crystal River Florida
United States Dallas Diabetes and Endocrine Center Dallas Texas
United States Research Institute of Dallas Dallas Texas
United States Global Medical Research DeSoto Texas
United States Radiant Research, Inc. Edina Minnesota
United States Skyline Medical Center Elkhorn Nebraska
United States Clinical Research Advantage Evansville Indiana
United States Fountain Hills Family Practice, P.C. Fountain Hills Arizona
United States American Health Network of Indiana, LLC Franklin Indiana
United States Prestige Clinical Research Franklin Ohio
United States Research Center of Fresno, Inc. Fresno California
United States Thomas C. Lenzmeier, M.D., P.C. Glendale Arizona
United States Marin Endocrine Care and Research, Inc. Greenbrae California
United States Medication Management, LLC Greensboro North Carolina
United States Harleysville Medical Associates Harleysville Pennsylvania
United States HealthCare Research Network Hazelwood Missouri
United States Nevada Family Care Henderson Nevada
United States Indago Research and Health Center, Inc. Hialeah Florida
United States Juno Research Houston Texas
United States PCP for Life - -Tidwell Houston Texas
United States National Research Institute Huntington Park California
United States Clinical Neuroscience Solutions, Inc. Jacksonville Florida
United States Sante Clinical Research Kerrville Texas
United States Wells Institute for Health Awareness Kettering Ohio
United States Holston Medical Group, P.C. Kingsport Tennessee
United States Palm Research Center, Inc. Las Vegas Nevada
United States Scott Research Center Laurelton New York
United States Columbine Family Practice Littleton Colorado
United States National Research Institute Los Angeles California
United States Clinical Research Institute of Southern Oregon, PC Medford Oregon
United States Clinical Neuroscience Solutions, Inc. Memphis Tennessee
United States Solaris Clinical Research Meridian Idaho
United States Research Institure of South Florida Miami Florida
United States Oklahoma City Clinic - Midwest City Midwest City Oklahoma
United States Catalina Research Institute Montclair California
United States Down East Medical Associates, PA Morehead City North Carolina
United States Radiant Research Murray Utah
United States American Health Network of Indiana, LLC New Albany Indiana
United States Intend Research Norman Oklahoma
United States Providence Clinical Research North Hollywood California
United States Lynn Health Science Institute Oklahoma City Oklahoma
United States Oklahoma City Clinic - Central Oklahoma City Oklahoma
United States Clinical Neuroscience Solutions, Inc. Orlando Florida
United States Overland Park Surgical Specialists, LLL dba College Park Family Care Center Overland Park Kansas
United States Palm Harbor Medical Associates Palm Harbor Florida
United States Andres Patron, D.O., P.A Pembroke Pines Florida
United States South Broward Research Pembroke Pines Florida
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania
United States Central Phoenix Medical Center Phoenix Arizona
United States Family Practice Specialists Phoenix Arizona
United States Preferred Primary Care Phys Inc Pittsburgh Pennsylvania
United States Sound Healthcare Port Orchard Washington
United States Clinical Research of Rock Hill Rock Hill South Carolina
United States Center for Clinical Trials of Sacramento, Inc. Sacramento California
United States Health Texas Research Institute San Angelo Texas
United States Clinical Trials of Texas, Inc. San Antonio Texas
United States MacGregor Medical Center San Antonio Texas
United States Panacea Clinical Research San Antonio Texas
United States Victorium Clinical Research Ltd. San Antonio Texas
United States Medical and Procedural Specialists Skokie Illinois
United States Spartanburg Medical Research Spartanburg South Carolina
United States HSHS Medical Group DIabetes Research Springfield Illinois
United States Fiel Family and Sports Medicine Tempe Arizona
United States University of Toledo Toledo Ohio
United States Cotton O'Neil Clinical Research Center Topeka Kansas
United States Arizona Community Physicians Tucson Arizona
United States Orange Grove Family Practice Tucson Arizona
United States Preferred Primary Care Physicians Uniontown Pennsylvania
United States Crossroads Clinical Research, LLC Victoria Texas
United States Advanced Clinical Research West Jordan Utah
United States Heartland Research Associates, LLC Wichita Kansas
United States Heartland Research Associates, LLC Wichita Kansas
United States PMG Research of Wilmington, LLC Wilmington North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Intarcia Therapeutics

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction in glycosylated hemoglobin A1c To determine whether ITCA 650 is non-inferior either to empagliflozin or to glimepiride in reducing glycosylated hemoglobin A1c (HbA1c) in patients with T2D following 65 weeks of treatment and 4 weeks of post treatment follow up. Randomization to 69 weeks
Primary Reduction in weight To determine whether ITCA 650 is non-inferior either to empagliflozin or to glimepiride in reducing weight in patients with T2D following 65 weeks of treatment and 4 weeks of post treatment follow up. Randomization to 69 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2